A PHASE I MASTER PROTOCOL OF NOVEL COMBINATION THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL LYMPHOMA.
- Registry ID
- LY.18
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY
- Start date
- 2021-10-05
- Last update
- 2019-12-04
Conditions
- B-CELL NON-HODGKIN'S LYMPHOMA
- DIFFUSE LARGE B-CELL LYMPHOMA
Related clinical trials
- A PHASE 1/2 OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF GSK5926371 IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
- Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
- AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY OF
ZILOVERTAMAB VEDOTIN (MK-2140) IN COMBINATION WITH R-CHP
VERSUS R-CHOP IN PARTICIPANTS WITH PREVIOUSLY UNTREATED DIFFUSE
LARGE B-CELL LYMPHOMA (DLBCL) (WAVELINE-010)
- A MODULAR PHASE II, SINGLE-ARM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD0486 IN PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (SOUNDTRACK-B)
- A PROSPECTIVE, MULTICENTER, PHASE II TRIAL TO EVALUATE THE EFFICACY OF ZANUBRUTINIB
AND TISLELIZUMAB AS WELL AS STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH
PROGRESSIVE LYMPHOMA POST ANTI-CD19 CAR-T CELL THERAPY (ZETA)
View on source registry